ANA ISABEL
SÁNCHEZ FRUCTUOSO
Profesora titular de universidad
Juan Carlos
Ruiz San Millán
Publicaciones en las que colabora con Juan Carlos Ruiz San Millán (23)
2023
-
Lymphoproliferative disorders after renal transplantation along 2 decades: A large longitudinal study of 21,546 recipients
Nefrologia, Vol. 43, Núm. 4, pp. 427-434
-
Lymphoproliferative disorders after renal transplantation along 2 decades: a large longitudinal study of 21.546 recipients
Nefrologia, Vol. 43, Núm. 4, pp. 427-434
-
Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients
Nefrologia, Vol. 43, Núm. 5, pp. 531-545
2020
-
Effectiveness and safety of the conversion to MeltDose® extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study
Clinical Transplantation, Vol. 34, Núm. 1
-
Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients
Nefrologia, Vol. 40, Núm. 3, pp. 265-271
2019
2012
-
Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: The AnemiaTrans study
Advances in Therapy, Vol. 29, Núm. 11, pp. 979-991
-
Everolimus as primary immunosuppression in kidney transplantation: Experience in conversion from calcineurin inhibitors
Transplantation, Vol. 93, Núm. 4, pp. 398-405
-
Management of proteinuria in clinical practice after kidney transplantation
Transplantation Reviews, Vol. 26, Núm. 1, pp. 36-43
2011
-
Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients
American Journal of Transplantation, Vol. 11, Núm. 9, pp. 1965-1971
2010
-
Anemia control in kidney transplant patients treated with methoxy polyethylene glycol-epoetin beta (Mircera): The anemiatrans group
Transplantation Proceedings, Vol. 42, Núm. 8, pp. 2931-2934
-
Comparative analysis of adverse events requiring suspension of mTOR inhibitors: Everolimus versus sirolimus
Transplantation Proceedings, Vol. 42, Núm. 8, pp. 3050-3052
-
Protección inmunológica del injerto
Permanyer
2009
-
Use of Mycophenolate Sodium in Stable Renal Transplant Recipients in Spain: Preliminary Results of the MIDATA Study
Transplantation Proceedings, Vol. 41, Núm. 6, pp. 2309-2312
2007
-
Early Sirolimus Use With Cyclosporine Elimination Does Not Induce Progressive Proteinuria
Transplantation Proceedings, Vol. 39, Núm. 7, pp. 2151-2152
-
Evaluation of the Efficacy and Safety of the Conversion From a Calcineurin Inhibitor to an Everolimus-Based Therapy in Maintenance Renal Transplant Patients
Transplantation Proceedings, Vol. 39, Núm. 7, pp. 2148-2150
-
Use of the New Proliferation Signal Inhibitor Everolimus in Renal Transplant Patients in Spain: Preliminary Results of the EVERODATA Registry
Transplantation Proceedings, Vol. 39, Núm. 7, pp. 2157-2159
2006
-
Conversion to Everolimus in Kidney Transplant Recipients: A Safe and Simple Procedure
Transplantation Proceedings, Vol. 38, Núm. 8, pp. 2424-2426
-
Conversión a sirolimus
Nefrologia, Vol. 26, Núm. SUPPL.2, pp. 52-63
-
Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction
Nephrology Dialysis Transplantation, Vol. 21, Núm. 11, pp. 3252-3257